

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, C12N 15/00, 15/85, C07H 21/04</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/50457</b>
			<b>(43) International Publication Date:</b> 7 October 1999 (07.10.99)
<b>(21) International Application Number:</b> PCT/US99/06742			<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(22) International Filing Date:</b> 28 March 1999 (28.03.99)			
<b>(30) Priority Data:</b> 60/079,792 28 March 1998 (28.03.98) US 60/107,504 6 November 1998 (06.11.98) US			
<b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; 210 Park Building, Salt Lake City, UT 84112 (US).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RUFFNER, Duane, E. [US/US]; 1966 Downington Avenue, Salt Lake City, UT 84108 (US). PIERCE, Michael, L. [US/US]; 2511 East 2860 South, Salt Lake City, UT 84109 (US). CHEN, Zhidong [CN/US]; 1901 E. Sunnyside Avenue, Salt Lake City, UT 84108 (US).  <b>(74) Agents:</b> HOWARTH, Alan, J. et al.; Clayton, Howarth & Cannon, P.C., P.O. Box 1909, Sandy, UT 84091-1909 (US).			
<b>(54) Title:</b> DIRECTED ANTISENSE LIBRARIES			
<b>(57) Abstract</b> <p>A method for making a directed antisense library against a target transcript is described. A cDNA of the target transcript is cloned in an appropriate cloning vector. Next, a plurality of deletion derivatives of the cloned cDNA is prepared such that the deletions serially extend into the cDNA from one end thereof. The resulting deletion library is then treated such that cDNA is removed from the other end of each cDNA insert, thus obtaining a fragment library having fragments of a selected size. An antisense gene is then inserted into each fragment of the fragment library, resulting in the directed antisense library. An illustrative antisense gene in the hammerhead ribozyme catalytic core. Plasmids for making the antisense library, plasmids and methods for making the fragment library, and a method for identifying target sites for antisense-mediated gene inhibition are also described.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## DIRECTED ANTISENSE LIBRARIES

### BACKGROUND OF THE INVENTION

This invention relates to antisense agents. More particularly, the invention relates to compositions and methods for generation of directed antisense libraries and methods of use thereof wherein the antisense agents in the libraries can potentially bind to every binding site on a selected RNA transcript.

Antisense RNA, DNA, and ribozymes have been widely studied as research tools and potential therapeutic agents for inhibiting the expression of specific genes. These agents operate by binding to a complementary region on an RNA transcript produced from the gene of interest. On binding, the antisense agent can prevent expression of the RNA, and this can occur through a variety of different mechanisms. There are many sites on any given RNA for targeted inhibition by an antisense molecule. For a typical RNA transcript of 2000 nucleotides, just under 2000 target sites are available. Examination of a few to tens of randomly chosen target sites reveals a great variability in activity. Clearly, not all target sites are equivalent in their ability to permit antisense mediated inhibition. Consequently, identification of effective target sites on the RNA transcript for interaction with the antisense molecule is imperative for successful application of antisense technology. Methods currently available for this purpose include the use of computer algorithms to predict target accessibility based on the predicted secondary structure of the mRNA, the use of randomized oligonucleotide and ribozyme libraries in cell free systems, and the examination of a few to tens of antisense oligonucleotides, targeted to arbitrarily chosen sites, in cell culture assays. These approaches have met with limited success.

To identify the most effective target site(s), the following conditions should be met. First, all possible sites on the target RNA should be evaluated. Second, evaluation should be carried out in the normal cellular milieu. This insures that the target is in its natural structure, associated with its normal complement of cellular factors. Additionally, the antisense agent has the opportunity to act on alternate structures that may arise as a result of the many RNA processing reactions.

To evaluate all target sites, antisense libraries must be used. These libraries should contain antisense molecules targeted to every site. One approach is the use of completely randomized DNA, RNA, or ribozyme libraries. The use of completely randomized libraries suffers from two major disadvantages. First, while such libraries may contain antisense molecules directed at all sites on the target RNA, they also contain antisense molecules directed

at all sites of all potential RNA transcripts produced by the cell. Therefore, these random libraries potentially have the capability to inhibit expression of every gene in the cell. Because of this, random libraries are limited to *in vitro* use in cell free assays. Second, the complexity of these libraries is enormous. For example, a random library that uses 14 nucleotides to recognize its target must contain at least  $2.6 \times 10^8$  (i.e.,  $4^{14}$ ) different members. Realistically, the size of the library must be at least 10- to 100-fold greater in size to insure representation of all sequences. The production and screening of such large libraries is likely beyond current capabilities.

Herein there is described a new method for identifying optimal antisense target sites against any desired RNA transcript. This is a directed library approach. In other words, this approach uses an antisense library that targets every site on any selected RNA and only sites present on the selected RNA. This library, therefore, does not inhibit other non-target RNA transcripts. This approach is also an improvement over known methods because it uses relatively small libraries. For example, a library targeting an RNA transcript of 2000 nucleotides, and using 14 nucleotides to recognize its target, theoretically needs 1986 members. In practice, the library would need to be 10- to 50- times this size. At 50 times, or 99,300 members, this is still a relatively small library. These directed libraries can be used in both *in vitro* and *in vivo* assays for the detection of effective target sites for antisense mediated gene inhibition.

In view of the foregoing, it will be appreciated that a method for generating directed antisense libraries would be a significant advancement in the art. Herein is described a method for examining the entire length of any RNA transcript for sites that are accessible to antisense agents. This approach allows for the localization of the most effective sites for targeting with antisense agents.

## BRIEF SUMMARY OF THE INVENTION

It is an object of the present invention to provide a simple and inexpensive method for producing directed antisense libraries against any selected RNA transcript.

It is also an object of the invention to provide a method of producing directed antisense libraries wherein such libraries contain antisense agents directed against all targets spanning the entire selected RNA transcript.

It is another object of the invention to provide a method of using directed antisense libraries for locating efficient target sites on the selected RNA transcript.

It is still another object of the invention to provide compositions for use in constructing directed antisense libraries.

It is yet another object to provide a method for making fragment libraries of a selected size of DNA fragment inserted in a cloning vector.

5        These and other objects can be addressed by providing a method for generating an antisense library targeted to a selected RNA transcript comprising:

(a)     preparing a double-stranded cDNA, comprising a first end, a second end, and a central site thereof, from the selected RNA transcript and cloning the cDNA in a cloning vector comprising a promoter configured such that an antisense transcript of the cDNA is synthesized upon transcription mediated by the promoter, resulting in a cloned cDNA;

10        (b)     creating a plurality of deletion derivatives of the cloned cDNA wherein each of the plurality of deletion derivatives has a deletion extending from the first end into the cloned cDNA such that the plurality of deletion derivatives comprises a deletion library comprising deletions extend serially into the cDNA;

15        (c)     reducing the size of the cDNA contained in the deletion library to a preselected size by removing a portion of the cDNA from the second end thereof to result in a fragment library;

(d)     inserting an antisense gene DNA into the central site of the cDNA in the fragment library, thereby obtaining the antisense library.

20        Preferred cloning vectors comprise multi-cloning sequences comprising SEQ ID NO:1 and a combination of SEQ ID NO:2 and SEQ ID NO:3. In a preferred embodiment of the invention, the deletion derivatives are created with exonuclease III resection of the cloned cDNA. The size of the cDNA contained in the deletion library is preferably reduced to a preselected size by digesting the deletion library with a type IIS restriction endonuclease.

25        Further, inserting the antisense gene DNA into the central site of the cDNA in the fragment library preferably comprises digesting the fragment library with a type IIS restriction endonuclease, thereby creating the central site, and ligating the antisense gene DNA at the central site. A preferred antisense gene comprises a ribozyme catalytic core, more preferably, a hammerhead ribozyme catalytic core.

30        Another aspect of the invention relates to a method for generating a library of DNA fragments of a selected size wherein the fragments collectively span all possible sites of the selected size in a source DNA comprising a first end, a second end, and a central site thereof, comprising:

- (a) cloning the source DNA in a cloning vector;
- (b) creating a plurality of deletion derivatives of the cloned source DNA wherein each of the plurality of deletion derivatives has a deletion extending from the first end into the cloned DNA such that the plurality of deletion derivatives comprises a deletion library
- 5 comprising deletions extend serially into the cloned DNA; and
- (c) reducing the size of the DNA contained in the deletion library to a preselected size by removing a portion of the DNA from the second end thereof to result in the library of fragments.

Still another aspect of the invention relates to a method for identifying target sites for  
10 antisense-mediated inhibition of a selected gene comprising:

- (a) constructing a directed antisense library targeted at the selected gene wherein the library is contained in a cloning vector having a promoter configured for transcribing antisense transcripts from the directed antisense library in suitable cells wherein the selected gene is expressed as a target transcript;
- 15 (b) transforming a plurality of the suitable cells such that each of the plurality of suitable cells transcribes an antisense transcript that has access to the target transcript for potential inactivation thereof;
- (c) identifying a cell wherein an antisense transcript inactivates the target transcript; and
- 20 (d) analyzing the antisense transcript that inactivates the target transcript and determining a target site on the antisense transcript that is associated with inactivation of the target transcript.

Yet another aspect of the invention relates to a method for identifying target sites for antisense-mediated inhibition of a selected gene comprising:

- 25 (a) constructing a directed antisense library targeted at the selected gene wherein the library is contained in a cloning vector having a promoter configured for transcribing antisense transcripts from the directed antisense library *in vitro*;
- (b) transcribing antisense transcripts from the directed antisense library *in vitro*;
- (c) incubating the antisense transcripts with a lysate from a cell containing target
- 30 transcripts transcribed from the selected gene such that antisense transcripts targeted to the target transcripts bind to such target transcripts; and
- (d) analyzing the antisense transcripts that bind the target transcript and determining a target site on the antisense transcript that is associated with binding of the target transcript.

## BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

FIGS. 1A and 1B show illustrative multi-cloning sequences (MCS's) according to an aspect of the present invention.

FIG. 2 summarizes an illustrative method for making a DNA fragment library containing 14 bp fragments according to the present invention.

FIG. 3 shows a schematic representation of a hammerhead ribozyme bound to a target substrate; the hammerhead ribozyme comprises a catalytic core that cleaves the substrate at the cleavage site indicated by the arrow and a recognition domain for binding to the substrate by base pairing.

FIG. 4 summarizes an illustrative method for making a hammerhead ribozyme library from an antisense RNA library according to the present invention.

FIG. 5A shows an illustrative method for inserting a selected cassette at an end of a deletion fragment in a deletion fragment library according to the present invention.

FIG. 5B shows an illustrative method for inserting a selected cassette in a MCS prior to preparation of a deletion fragment library according to the present invention.

FIG. 6A shows a map of expression vector pBK, which is suitable for use in identifying antisense targets in mammalian cells according to the present invention.

FIG. 6B shows base pairing of nucleotides in a multi-cloning sequence flanked by cis-acting ribozymes (CAR's).

FIG. 7A shows a map of vector pASlib according to the present invention.

FIG. 7B shows a map of vector pShuttle according to the present invention.

FIG. 7C shows a map of the MCS of pShuttle according to the present invention.

FIG. 8 shows a histogram of the distribution of 56 target sites in an illustrative antisense library according to the present invention.

## DETAILED DESCRIPTION

Before the present compositions and methods for generating directed antisense libraries and methods of use thereof are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out herein.

5           As used herein, "antisense agent" and similar terms mean antisense RNA, antisense DNA, and ribozymes.

          As used herein, "comprising," "including," "containing," "characterized by," and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps. "Comprising" is to be interpreted as including  
10           the more restrictive terms "consisting of" and "consisting essentially of."

          As used herein, "consisting of" and grammatical equivalents thereof exclude any element, step, or ingredient not specified in the claim.

          As used herein, "consisting essentially of" and grammatical equivalents thereof limit the scope of a claim to the specified materials or steps and those that do not materially affect the  
15           basic and novel characteristic or characteristics of the claimed invention.

#### Construction of Directed Antisense Libraries

          The present invention includes a procedure that allows construction of directed antisense libraries of a variety of types. This requires the use of specially designed bacterial and/or mammalian plasmid vectors. Most importantly, these vectors possess a specially designed  
20           multi-cloning sequence (MCS). This approach is not restricted to a single MCS, as many can be designed that allow the procedure to be performed. Two illustrative MCS's are shown in FIGS. 1A (SEQ ID NO:1) and 1B (SEQ ID NO:2 and SEQ ID NO:3). These simply illustrate two possible multi-cloning sequences that could be used for this method. While some of the same restriction enzyme sites are used in both of these MCS's, such particular sites are not necessarily  
25           the only sites that could be used. Many other restriction enzyme sites could substitute for any of the restriction sites, allowing the same procedure to be performed.

          The procedure uses a special multi-cloning sequence and a series of enzymatic manipulations to produce DNA fragment libraries directed against any desired gene of interest. The fragment libraries contain all overlapping fragments spanning the entire length of the gene  
30           of interest. Transcription *in vitro* or *in vivo* of the DNA fragment allows the production of an antisense RNA targeted to the site on the RNA transcript that is encoded by the DNA fragment. Transcription of the entire DNA fragment library produces all antisense RNA molecules



targeting all positions on the RNA target. Expression of the library in mammalian cells allows identification of effective target sites for antisense-mediated gene inhibition.

The procedure is illustrated in FIG. 2 using the MCS shown in FIG. 1A. Beginning with the MCS 10 in a suitable circular plasmid vector (described in more detail below), a blunt-ended DNA fragment encoding the gene of interest 14 is ligated into the EcoRV-digested MCS (FIG. 2, step a). Since the gene can be inserted in one of two orientations, a clone is selected, according to methods well known in the art such as nucleotide sequencing or restriction mapping, wherein the gene insert is suitably oriented. The orientation will depend on the placement of a transcriptional promoter adjacent to the MCS. The orientation of the insert will be chosen such that the antisense strand of the insert will be transcribed by the adjacent promoter. Next, a deletion library is prepared. The plasmid containing the gene of interest is digested with both PmeI and BbeI (FIG. 2, step b). The BbeI terminus is protected from exonuclease III digestion because of its 3' overhang 18, while the PmeI terminus 22 is a suitable substrate therefor. The digested plasmid is then treated with exonuclease III and aliquots are removed over time into a stop mixture (FIG. 2, step c). The time points are chosen such that deletions are generated after every nucleotide across the entire gene. After exonuclease III digestion, the combined aliquots are treated with mung bean nuclease to remove the resulting 5' overhang (FIG. 2, step c). The termini are then polished with T4 DNA polymerase (FIG. 2, step d) and the plasmid is re-circularized with T4 DNA ligase to produce the deletion library (FIG. 2, step e). The deletion library is then converted into a fragment library (14 base-pair fragments 26 in this case) by digestion with restriction endonucleases BsmI and BpmI (FIG. 2, step f), purification of the plasmid containing the 14 bp fragment 26 from the excised BpmI/BsmI fragment 30 (FIG. 2, step g), end-polishing with T4 DNA polymerase (FIG. 2, step h), and ligation with T4 DNA ligase (FIG. 2, step i). Not stated, but implied, after each ligation step (i.e., steps a, e, and i) the ligation mixture is transformed into bacteria, the DNA is recovered from the bacteria, and the recovered DNA is used in the subsequent step. All of these reactions involving restriction endonucleases, ligases, polymerases, nucleases, and the like are well known in the art and are performed according to standard methods, e.g., J. Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2d ed., 1989); T. Maniatis et al., *Molecular Cloning: A Laboratory Manual* (1982); F. Ausubel et al., *Current Protocols in Molecular Biology* (1987), relevant parts of which are hereby incorporated by reference.

The essence of the procedure is as follows. A gene of interest is converted into a library of fragments serially deleted after every nucleotide. This deletion library is subsequently

converted into a fragment library containing all overlapping fragments encoded by the gene.

The fragment library can also serve as the starting point for construction of other types of antisense libraries. One such library is an antisense hammerhead ribozyme library.

5 A hammerhead ribozyme 34 is a small RNA that can catalyze the cleavage of a complementary RNA target 38 (FIG. 3). The hammerhead comprises a catalytic core 42 (SEQ ID NO:4), essential for cleavage activity. Additionally, the hammerhead has a recognition domain 46 that is required for interaction with a complementary substrate, such as an RNA transcript. There are few sequence requirements for the recognition domain, thus by changing the sequence of the recognition domain almost any sequence can be targeted for cleavage by the  
10 hammerhead. Cleavage of the substrate 38 occurs at a cleavage site 50 containing an NUH sequence (where N is A, C, G, or U and H is A, C, or U). In the case where the substrate is a gene transcript, the hammerhead can be used as an antisense inhibitor of gene expression.

To convert the fragment (antisense RNA) library into a hammerhead ribozyme library, a DNA fragment encoding the hammerhead catalytic core is inserted into the DNA fragment  
15 encoding the antisense RNA. This is performed as illustrated in FIG 4. The 14 base-pair fragment 54 in the fragment library is bisected with HphI (FIG. 4, step a). The resulting single-stranded overhang on each terminus is then removed using the 3' to 5' exonuclease activity of T4 DNA polymerase (FIG. 4, step b) to result in blunt ends 58, 62. A DNA fragment encoding the hammerhead catalytic core 66 (SEQ ID NO:4) is then inserted by ligation (FIG. 4, step c). The  
20 catalytic core shown in FIG. 4 is interrupted by a promoter-less chloramphenicol resistance gene 70 (CAT). A promoter is provided flanking the MCS. Transforming bacteria and selecting for chloramphenicol resistance allows selection for clones in which the catalytic core is in the correct orientation to produce a bonafide hammerhead ribozyme. Next, the CAT gene is removed and the sequence encoding a hammerhead ribozyme 74 is generated by NruI digestion  
25 (FIG. 4, step d) and ligation with T4 DNA ligase (FIG. 4, step e).

Other types of antisense libraries can also be produced from the fragment library. For instance, other cassettes can be ligated into an HphI-digested fragment library. Catalytic cores from other ribozymes, including those currently known and those to be discovered, can be inserted. Additionally, other cassettes could be used that encode sequences that cause  
30 modification to the target by mechanisms other than cleavage. Similarly, ribozyme and non-ribozyme sequences can be added to the end of the antisense sequence. This is illustrated in FIG. 5A, wherein the DNA fragment library is digested with BpmI, which digests the DNA at the distal end of the inserted fragment 78 (step a). The unpaired nucleotides resulting from this

reaction are then removed with T4 DNA polymerase (step b) to result in blunt ends 82, 86. Next, a cassette 90 is inserted by ligation to recircularize the modified plasmid 94, now containing the cassette inserted at an end of the insert fragment. Alternatively, instead of inserting a cassette after the fragment library is produced, a suitable cassette can be engineered into the starting multi-cloning sequence. For instance, the HphI site of the original MCS (FIG. 1A) could be replaced with a cassette encoding any desired sequence (FIG. 5B). Then, using the same procedure illustrated in FIG. 2, the cassette can be placed against the fragment sequence in the conversion of the deletion library into the fragment library. An example of a possible cassette is one encoding the sequence CUGA. An antisense RNA with this sequence at its 3' end has been shown to be capable of directing the 2'-O-methylation of the complementary target (J. Cavaille et al., Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides, 383 Nature 732-735 (1996)). This reaction is catalyzed by modification machinery present in mammalian cells. 2'-O-methylation of a suitable target site could be used to inhibit expression of the RNA transcript. Other cellular RNA processing reactions can also be used in a similar fashion with the use of different cassettes placed adjacent to the antisense RNA sequence.

#### Use of Directed Libraries in the Identification of Target Sites for Antisense-Mediated Gene Inhibition

Antisense libraries prepared according to the present invention can be assayed *in vitro* in a cell free system or *in vivo* in cultured cells, as will be described in more detail below.

In vivo assay. For *in vivo*, use the antisense library is introduced by transfection into a suitable cell line that expresses the gene of interest. The transfection conditions are chosen such that only one member of the library is taken up by each individual cell. The individual cells then each express a different antisense molecule targeted to a different site on the RNA transcript of interest. All target sites are represented in the entire cell population produced by transfection. Using a suitable detection method, cell clones can be identified in which expression of the target RNA has been reduced or eliminated. These clones possess an antisense molecule that targets an effective site on the RNA transcript of interest. The plasmid encoding this antisense molecule is recovered and the target sequence is identified by DNA sequencing.

To identify suitable targets *in vivo*, specially designed expression vectors are required. One key feature of such expression vectors is that they are designed to replicate episomally in mammalian cells. FIGS. 6A and 7B show two such episomal vectors, pBK (SEQ ID NO:17)

and pShuttle (SEQ ID NO:14), respectively. Vector pBK possesses the origin of replication and the gene encoding the T/t antigen from the human papova virus BK (BKV). Vector pShuttle possesses the origin of replication and the EBNA1 gene from the human Epstein-Barr virus (EBV). These sequence elements allow each of the plasmids to replicate extrachromosomally (episomally). Episomal expression is desirable for several reasons. First, it eliminates the clone-to-clone variation in expression that occurs if stable transfectants are used. P.B. Belt et al., 84 Gene 407-417 (1989). Second, since the copy number of the episomal vector is determined primarily by the transfection conditions and, once established, remains tightly regulated, J.L. Yates & N. Guan, 65 J. Virol. 483-488 (1991), then effects on expression due to differences in copy number are minimal. Consequently, the selection of antisense efficacy is based on accessibility and not the level of expression. Third, the use of an episomal expression vector allows for high transfection efficiency. P.B. Belt et al., 84 Gene 407-417 (1989); R.F. Maragolskee et al., 8 Mol. Cell. Biol. 2837-2847 (1988). This is important to ensure that all antisense agents present in the library are represented in the mammalian transfectants. Finally, the plasmid can be recovered and shuttled back into bacterial cells. This allows the sequence of effective antisense agents to be determined, thereby identifying accessible target sites. As a demonstration of episomal replication, pShuttle was used to transfect HeLa cells, and the cells were grown in culture under 400  $\mu$ g/ml hygromycin selection. After 1 month in culture, low molecular weight DNA was isolated from  $1 \times 10^7$  cells and used to transform *Escherichia coli* DH5 $\alpha$ , producing a total of 2475 hygromycin-resistant colonies.

Vector pBK illustrates other features of value for *in vivo* expression of antisense libraries. pBK has a single antibiotic resistance gene, bleomycin<sup>R</sup>, driven by dual mammalian (CMV) and bacterial (em7) promoters. This allows the same selectable marker to be used in both bacterial and mammalian cells. This helps to minimize the size of the vector, since large vectors transfect at a lower efficiency. pBK has both the BK origin of replication and the origin of replication from the pUC series of bacterial plasmids. Therefore pBK can be replicated in both bacterial and mammalian cells, and can be shuttled between them. pBK was designed such that the antisense library could be constructed and expressed from the same vector. The antisense sequence is expressed by read-through expression of the bleomycin<sup>R</sup> gene. This ensures expression of the antisense agent when the cells are grown in the presence of bleomycin. The antisense fragment is released from the larger bleomycin transcript by the activity of cis-acting ribozymes (CAR), hammerhead ribozymes in this case, that flank the antisense sequence. In the absence of CAR, flanking sequences of the larger bleomycin transcript could inhibit the

activity of the antisense agent. Sequences outside of the MCS (FIG. 1A) encode the cis-acting ribozymes. They are illustrated in FIG. 6B where only the sequence of the upper strand of the MCS is shown (SEQ ID NO:18). On cleavage by the CAR, the antisense agent is released and stable hairpin loops form to increase the nuclease resistance of the antisense agent.

5 pShuttle shares many of the same features as pBK, with two significant differences. First, this episomal vector is EBV-based rather than BKV-based. The second and more significant difference is that construction of the antisense library is not possible in pShuttle. Instead, the antisense library is first constructed in pASlib (SEQ ID NO:7), and subsequently transferred to pShuttle for expression in mammalian cells. The antisense encoding fragment of pASlib is removed by digestion with HindIII and SalI (Figure 7A). Subsequently, the HindIII/SalI  
10 fragment is ligated into the multi-cloning site of pShuttle via the HindIII and XhoI sites (Figure 7C). This places the antisense sequence downstream of a dual CMV/T7 promoter for expression *in vivo* in mammalian cells or, alternatively, *in vitro* by transcription using T7 RNA polymerase.

Although it is believed that episomal shuttle vectors are advantageous for expression of  
15 directed antisense libraries, viral vectors can also be used. Many viruses are currently being examined for expression of foreign genes for the purpose of gene therapy. These same viral vectors would be suitable for expression of directed antisense libraries. Some of these vectors replicate extrachromosomally and therefore behave similarly to the described episomal vectors. Others integrate into chromosomes. For the use of integrative viral vectors, two minor problems  
20 would need to be dealt with. First, the antisense gene present within the viral vector would integrate into the chromosome with the virus. Consequently, recovering the gene to determine the site at which it targets is not readily possible. This can be dealt with by using polymerase chain reaction (PCR) to amplify the integrated antisense gene. The PCR product could be sequenced directly, or cloned and sequenced to identify the target site. Second, some of these  
25 viral vectors integrate randomly and this would produce differing levels of expression from different members of the directed antisense library. As discussed, it is important that expression of all members of the library be comparable. This problem can be dealt with by using a viral vector that integrates at a specific preferred site, such as adeno-associated virus.

*In vitro* assay. Identification of effective antisense target sites using antisense libraries  
30 can also be performed using *in vitro* assays. For instance, an assay such as that used by Lieber and Strauss (A. Lieber & M. Strauss, Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library, 15 Molecular and Cellular Biology 540-551 (1995)), can be used. For this, the antisense library is produced by *in vitro* transcription from a suitable

promoter. In the present case, an antisense ribozyme library in pShuttle might be used. Of course other types of antisense libraries could be used similarly. The library-containing pShuttle is digested with XbaI and used as a template for run-off transcription of the antisense ribozyme by *in vitro* transcription with T7 RNA polymerase, according to methods well known in the art (e.g., C.J. Noren et al., 18 Nucleic Acids Res. 83-88 (1990). Subsequently, the transcribed ribozyme library is incubated in a lysate prepared from a mammalian cell line expressing the gene of interest. Effective target sites are identified by performing a primer extension reaction on purified RNA from the lysate using a primer specific for the gene of interest. Primer extension products terminate at the sites of cleavage by effective ribozymes. These sites are identified by gel electrophoresis of the primer extension products with suitable size markers.

### Example 1

Construction of pASlib. In this example, there is described an illustrative plasmid according to the present invention for making a deletion library of a selected DNA. This plasmid was constructed as follows.

The HindIII-HpaI fragment of pLA2917 (J.N. Allen & R.S. Hanson, 161 J. Bact. 955-962 (1985)), containing the kanamycin resistance gene, was inserted into HindIII/SmaI-digested pUC19 to produce pUCKan. An HphI and two BsaHI sites were eliminated from the kanamycin resistance gene by site-directed mutagenesis, according to methods well known in the art, to produce pUCKan\*. The mutagenized kanamycin resistance gene was removed by HindIII/EcoRI digestion, and the termini were blunted by 5'-overhang fill-in using the Klenow fragment of DNA polymerase I and ligated to the 843 bp BspHI-SapI fragment of pUC19 containing the origin of replication. A clone (pKan) was selected wherein the EcoRI and BspHI sites were juxtaposed. The BsmFI and PstI sites were eliminated from pKan by site-directed mutagenesis using the procedure of E. Merino et al., 12 Biotechniques 508-510 (1992). The multiple cloning site for pASlib was constructed from the overlapping oligodeoxynucleotides MCS-L (SEQ ID NO:5) and MCS-R (SEQ ID NO:6) by 5'-overhang fill-in with the Klenow fragment of DNA polymerase I. Oligonucleotides were synthesized using an Applied Biosystems automated oligonucleotide synthesizer. The double-stranded multiple cloning site was inserted into EcoRI-linearized and blunted pKan to result in pASlib (SEQ ID NO:7). Restriction endonuclease digestions, primer extension reactions, ligation reactions, and the like were carried out according to methods well known in the art. E.g., J. Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., 1989); T. Maniatis et al., Molecular Cloning: A

Laboratory Manual (1982); F. Ausubel et al., Current Protocols in Molecular Biology (1987).

Therefore, pASlib possesses the pUC19 origin of replication and a kanamycin resistance gene allowing selection in bacterial cells. The kanamycin resistance gene was chosen as the selectable marker since, of all the available bacterial selection markers, it possessed the fewest sites present in the MCS. Therefore, it was the simplest to modify by site-specific mutagenesis to eliminate the undesirable sites. The MCS contains the following salient features. It possesses a short polylinker that allows much flexibility in the cloning of the gene or cDNA sequence of interest, which represents the first step in the construction of an antisense library. The polylinker includes several restriction sites that leave sticky ends upon digestion. These sites can be used to directionally clone the cDNA or genomic fragment in the correct orientation. Alternatively, the fragment can be cloned by blunt-end ligation, and the correctly oriented clone can be selected by restriction analysis. The PstI and PmeI sites allow the generation of a substrate for unidirectional digestion by exonuclease III into the cloned cDNA or genomic fragment. This allows preparation of a serial deletion library of the cloned insert. The BsmFI and BbsI sites are used together to convert the deletion library into a 14 bp fragment library. The HphI site allows bisection of the 14 bp fragment library for introduction of the antisense agent.

### Example 2

Construction of pShuttle. In this example, there is described the construction of an illustrative plasmid for use according to the present invention for expressing an antisense agent in either mammalian cells using the intermediate-early promoter from cytomegalovirus or *in vitro* using T7 polymerase.

A hygromycin expression cassette capable of being expressed in both mammalian and prokaryotic systems was constructed using overlap extension PCR. PCR was carried out according to methods well known in the art, e.g., U.S. Patent No. 4,683,195; U.S. Patent No. 4,683,202; U.S. Patent No. 4,800,159; U.S. Patent No. 4,965,188; PCR Technology: Principles and Applications for DNA Amplification (H. Erlich ed., Stockton Press, New York, 1989); PCR Protocols: A guide to Methods and Applications (Innis et al. eds, Academic Press, San Diego, Calif., 1990). The 1026 bp hygromycin resistance coding sequence from EBOP LPP (ATCC) was joined at its 3'-end to the 322 bp 3'-untranslated region (UTR)/SV40 early polyadenylation sequence from pRC/CMV (Invitrogen Corp., Carlsbad, California), while the 527 bp dual ampicillin/SV40 early promoter from pEGFP-1 was joined to the 5'-end. The sequences of the primers used in the PCR were as follows: 3'-UTR/poly(A) segment, SEQ ID NO:8 and SEQ ID

NO:9; hygromycin coding region, SEQ ID NO:10 and SEQ ID NO:11; amp/SV40 early promoter, SEQ ID NO:12 and SEQ ID NO:13. Each portion of the hygromycin cassette was prepared by PCR using one of the three primer sets and the appropriate template. The resulting fragments were gel purified. The hygromycin-encoding and the 3'-UTR/poly(A) fragments were  
5 combined and used in a second PCR reaction to produce the hygromycin-3'-UTR/poly(A) fragment. In a final PCR, this fragment was combined with the amp/SV40 fragment to produce the complete 1875 bp hygromycin gene cassette. The hygromycin gene cassette was ligated into the 843 bp BspHI-SapI oriP-containing fragment of pUC19, producing pHyg. The 4914 bp EcoRI-BamHI fragment containing the EBNA-1 and EBV oriP sequences from EBOpLPP was  
10 inserted between the hygromycin cassette and the pUC19 origin of XhoI-digested pHyg to make pEBV. The 1060 bp expression cassette was excised from pRC/CMV using NruI and PvuII and inserted into the BamHI site of pEBV to produce pShuttle (SEQ ID NO:14).

pShuttle was designed to allow replication and expression of the antisense library in mammalian cells. It possesses an MCS for insertion of the antisense library. The MCS is  
15 flanked on one end by a dual CMV/T7 promoter for allowing expression of the antisense agent gene both in mammalian cells as well as by *in vitro* transcription using T7 RNA polymerase. On the other end of the MCS is a bovine growth hormone polyadenylation signal for efficient expression in mammalian cells. pShuttle possesses a hygromycin resistance gene driven by a dual promoter for allowing selection in bacterial and mammalian cells. The pUC19 origin of  
20 replication allows replication in bacterial cells. For replication in mammalian cells, the EBV origin and EBNA-1 gene were included. J. Yates et al., 81 Proc. Nat'l Acad. Sci. USA 3806-3810 (1984); J. Yates et al., 313 Nature 812-815 (1985).

### Example 3

Construction of a hammerhead ribozyme catalytic core cassette. A cassette encoding the  
25 hammerhead catalytic core, interrupted by the CAT gene (S. Horinouchi & B. Weisblum, 150 J. Bact. 815-825 (1982)), was constructed as follows. PCR primers were prepared that were complementary to the CAT gene on their 3'-ends and encoded the hammerhead catalytic core on their 5'-ends. The sequences of the primers were SEQ ID NO:15 and SEQ ID NO:16. Located between the CAT and hammerhead catalytic core sequences were NruI restriction sites. The  
30 PCR contained 5 ng CAT gene DNA, 100 pmol each of the primers CatCass 1 and CatCass 2, 1 mM of each of the four dNTPs, 5 units of VENT polymerase (New England Biolabs, Beverly, Massachusetts) in the standard VENT polymerase buffer except that the concentration of the



MgSO<sub>4</sub> was increased to 5.2 mM (i.e., 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris-HCl (pH 8.8 at 24°C), 5.2 mM MgSO<sub>4</sub>, 0.1% Triton X-100). The use of VENT polymerase ensured that the cassette possessed blunt ends.

The reaction mixture was incubated as follows:

- 5 (A) 2 minutes at 94°C;
- (B) 5 cycles of 1 minute at 94°C, 30 seconds at 45°C, and 2 minutes at 72°C;
- (C) 15 cycles of 30 seconds at 94°C, 15 seconds at 60°C, and 2 minutes at 72°C; and
- (D) 5 minutes at 73°C.

10 After amplification, the cassette was purified from unincorporated primers by agarose gel electrophoresis, and the agarose was subsequently removed from the cassette DNA using standard procedures.

Introduction of a catalytic core into a fragment library presents several difficulties. The core must be inserted by blunt-end ligation and in the correct orientation to produce a functional ribozyme. Additionally, due to its small size, it is difficult to prevent the introduction of  
15 concatamers of the core and/or contamination of the library with clones that do not acquire a catalytic core. To increase the effectiveness and efficiency of this step, the core interrupted by the CAT gene was designed. CAT selection allows the use of a non-phosphorylated cassette. This prevents insertion of multimers and selects against non-recombinants. Additionally, the CAT gene allows selection of clones acquiring a correctly oriented catalytic core. In the desired  
20 orientation, transcription of the CAT and kanamycin genes is in the same direction. In the incorrect orientation, CAT expression is inhibited by antisense expression from the kanamycin resistance gene. This phenomenon has been noted previously, R. Bruckner et al., 32 Gene 151-1160 (1984). After selection, the CAT gene is removed by digestion with NruI to produce a sequence encoding a hammerhead ribozyme.

25

#### Example 4

Construction of a Herpes ICP4 ribozyme library. The 4489 bp BglII-EcoRI fragment from pTEG2, X.X. Zhu et al., 184 Virology 67-78 (1991), containing a herpes simplex virus ICP4 genomic fragment was cloned into *EcoRI-EcoRV*-digested pASlib. This fragment  
30 included 125 bp upstream of the translational start site, 466 bp downstream of the translational termination sequence, and the entire genomic coding sequence of ICP4. The resulting clone, pASlib-ICP4, contained the ICP4 fragment with the sense strand as the upper strand.

From pASlib-ICP4 a deletion library was produced as follows. Twenty µg of CsCl

gradient purified plasmid DNA was digested with *Pst*I and *Xba*I, then concentrated and desalted using a Microcon 50 spin filter (Amicon). The DNA was brought up to a volume of 60.4  $\mu$ l of exonuclease III buffer (i.e., 50 mM Tris-HCl, pH 8.0, 5 mM MgCl<sub>2</sub>, 10 mM 2-mercaptoethanol), warmed to 37°C, and then 300 units of exonuclease III were added. At 1-minute intervals after the addition of the exonuclease III, 2.5  $\mu$ l of the reaction mixture was removed and placed in microfuge tubes on ice containing 7.5  $\mu$ l of 66.7 mM sodium acetate, pH 5.2, 200 mM NaCl, 1.3 mM ZnCl<sub>2</sub>, and 1 unit of mung bean nuclease. After 25 aliquots had been removed, the mung bean nuclease-containing tubes were incubated at 20°C for 30 minutes. After 30 minutes, the contents of all of the mung bean nuclease-containing tubes were combined and extracted with phenol-chloroform (50:50), extracted with chloroform, and then were precipitated with two volumes of 100% ethanol. The DNA was then pelleted and dried. The DNA was then resuspended in 18  $\mu$ l of d.i. H<sub>2</sub>O, 2.5  $\mu$ l of 10 mM of each of the four dNTPs, 2.5  $\mu$ l of 10x *Pfu* polymerase buffer (e.g., 100 mM KCl, 100 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 200 mM Tris-Cl (pH 8.75), 20 mM MgSO<sub>4</sub>, 1% Triton® X-100, 1000 mg/ml BSA), and 5 units of *Pfu* polymerase (Stratagene, La Jolla, California), then incubated at 72°C for 15 minutes, and cooled to room temperature. The plasmid DNA was recircularized by ligating in a large volume (1.25 ml) in a buffer containing 5% PEG for 4 hours at room temperature. Except for the modifications indicated, all ligations were performed with T4 DNA ligase under the conditions suggested by the manufacturer.

After transformation into *E. coli* DH5 $\alpha$ , the cells were grown in liquid culture to amplify the deletion library. The library DNA was purified and digested with *Bsm*FI and *Bbs*I, and then the ends were blunted with *Pfu* polymerase as described above. The DNA was then recircularized by ligation in a 600  $\mu$ l volume in a buffer containing 5% polyethylene glycol (PEG) at room temperature for 4 hours. After transformation into *E. coli* DH5 $\alpha$ , amplification and plasmid purification, 1  $\mu$ g of library plasmid DNA was then subjected to digestion with 8 units of *Hph*I for 1 hour at 37°C, and the ends were polished with T4 DNA polymerase. The hammerhead core cassette was inserted by ligating 0.5  $\mu$ g of the *Hph*I-digested library DNA with 5  $\mu$ g of the ribozyme core sequence cassette prepared according to the procedure of Example 3. That ligation product was transformed into DH5 $\alpha$  and grown in culture under chloramphenicol selection. After purification, 2  $\mu$ g of the DNA was digested with *Hind*III and *Sal*I, and the terminal phosphates were removed using shrimp alkaline phosphatase (Amersham, Arlington Heights, Illinois). The *Hind*III/*Sal*I digest was fractionated on an agarose gel, and the dephosphorylated ribozyme/chloramphenicol cassette was purified using standard procedures. The cassette was combined with an equimolar amount of *Hind*III-*Xho*I-digested pShuttle,

prepared according to the procedure of Example 2, and ligated using a modified two-step ligation procedure, S. Damak & D.W. Bullock, 15 *Biotechniques* 448-450 (1993) (hereby incorporated by reference). The first step was performed at room temperature for 1 hour, and the second step was incubated overnight at 16°C. The ligation mixture was transformed in DH5 $\alpha$  and grown in culture under chloramphenicol selection. The library DNA was purified and then digested with NruI to release the chloramphenicol gene. The digested DNA was then recircularized by ligation in a volume of 600  $\mu$ l. The final ligation product was transformed into DH5 $\alpha$ , and the plasmid DNA was purified on a CsCl gradient.

To verify the effectiveness of this procedure, 56 clones obtained at various steps were sequenced. Thirty-one were from the final ribozyme library, and the remainder were from earlier steps, beginning with the 14 bp fragment library. The results of the sequencing are discussed below.

One observation made after the mung bean digestion was that the deletions infrequently stopped at A-T base pairs. While exonuclease III has been shown to exhibit a preference for stopping at certain nucleotides (C>A=T>G), W. Linxweiler & W. Horz, 10 *Nucleic Acids Res.* 4845-4859 (1982), this was not believed to be the cause of the observed sequence bias. Instead, it is believed that this is the result of a greater degree of "breathing" at A-T terminated deletions and the subsequent removal of A-T terminal pairs by mung bean nuclease. The mung bean nuclease digestion was later performed at higher salt concentrations (150 mM) and at a lower temperature (20°C). This eliminated the under-representation of A-T terminated deletions.

For construction of the library, two type IIS restriction enzymes are required, BsmFI and HphI. Typical of type IIS restriction enzymes, BsmFI and HphI cleave downstream of their recognition sequences in a sequence-independent manner. Cleavage by type IIS restriction enzymes can pose some problems since they can exhibit infidelity in how far from their recognition site they cleave. Cleavage by BsmFI was largely at the expected distance (10/14), but also at 11/15. The reported 9/13 activity for this enzyme, V.E. Velculescu et al., 270 *Science* 484-487 (1995), was not seen in any of the clones sequenced. Infidelity of BsmFI does not present a problem for construction of ribozyme libraries. The result of this infidelity is that the recognition domains of the ribozymes in the library can vary from 13 to 15 nucleotides.

In contrast, HphI infidelity can be problematical. HphI digestion is a critical step in the construction of ribozyme libraries. This enzyme produces a 1 nucleotide 3'-overhang that is later removed by polishing with T4 DNA polymerase. It is essential to the proper functioning of the resulting ribozyme that this 1 nucleotide be removed, since it does not have an antisense

binding partner in the ribozyme (FIG. 1, X).

HphI cleaves at 8/7, but also at 9/8. D. Kleid et al., 73 Proc. Nat'l Acad. Sci. USA 293-297 (1976). This infidelity is demonstrated in the present library by the presence of ribozymes with flanking helices of length 8 and 5, as would be expected if HphI cleaved at 9/8. This type of infidelity, in itself, is not problematical. It simply alters the relative lengths of the two arms of the binding domain, leaving the total length of the binding arms unchanged. The problem that arises with HphI infidelity is that the enzyme can cleave twice at the same target, i.e., if it first cleaves at 9/8 it can rebind and cleave at 8/7. The result is that 2 bp are removed from the sequence upon polishing with T4 DNA polymerase. Removal of 2 bp from the insertion site of the ribozyme core produces a non-functional ribozyme. In early attempts to produce a library, >40% of the clones were the product of double cutting. This is close to the statistically predicted 50% that would occur if HphI has no preference for either 8/7 or 9/8 cutting. To minimize the possibility of double cutting, HphI digestion was performed under near "single hit" conditions. Under these conditions, double cleavage was only 13% of the final library. It should be possible to further reduce the percentage of double hits by performing the cleavage under "sub-single hit" conditions. This should not present any problem so long as the amount of plasmid digested is sufficient to allow full representation of the ribozyme library. Undigested molecules cannot accept the catalytic core and are removed in the later step by selection for chloramphenicol resistance. Other class IIS restriction enzymes, such as MboII, could likely substitute for HphI, but fidelity may not be any better.

The infidelity of HphI raises another issue. It is possible that some sequences favor digestion at 8/7 and others at 9/8. This could lead to the absence of some ribozyme target sequences in the final library. This appears to be unlikely, however. First, as discussed, under conditions that give nearly 100% cleavage by HphI, >40% of the molecules are cut twice. This is close to the 50% predicted if HphI exhibits no preference for 8/7 versus 9/8 cutting. Second, two clones that both contain the same 14 bp sequence of ICP4, Rz8 and Rz9 (Table 1), are the products of 8/7 and 9/8 cleavage, respectively. This suggests that the intervening sequence between the binding site and the cleavage site does not affect where HphI cleaves.

HphI is also sensitive to overlapping dam methylation. This is also true of MboII. Since 2 nucleotides of the four base consensus sequence for dam methylation are provided by the variable sequence of the cDNA insert, mathematically 1/16 of the clones in the 14 bp fragment library (6.25%) will not be cleaved with HphI and will be eliminated from the final ribozyme library. This can be prevented by passage of the 14 bp fragment library in a dam<sup>-</sup> strain prior to

HphI digestion.

Table 1		
Clone (Position)	Target Sequence <sup>a</sup>	SEQ ID NO:
Rz1 (1754)	cgacgcccgcgcc	19
Rz2 (1992)	cugcgcgcguggcu	20
Rz3 (2045)	gcgccugcgcgggg	21
Rz4 (2252)	cgccgccgacgcgc	22
Rz5 (2411)	ccccuccccgcg	23
Rz6 (2517)	guggcccgugcgcg	24
Rz7 (2590)	gccacacggcgcg	25
Rz8 (2729)	cgccgcgcggugcg	26
Rz9 (2729) <sup>b</sup>	cgccgcgcggugcg	27
Rz10 (2837)	ccccugcgcgccuc	28
Rz11 (2915)	gguggugcuguacuc	29
Rz12 (3246)	gggcccgcgguguc	30
Rz13(3275) <sup>c</sup>	ccuggcgugcgagc	31
Rz14 (3569)	ggggaccaccgacgccauggc	32
Rz15 (3680)	cguggcgcgugggc	33
Rz16 (3842)	cgggauucgcuggg <sup>d</sup>	34

a The nucleotide in bold indicates the unbound nucleotide, i.e., position X in FIG. 3.

b Clone repeated 2 times.

c Clone repeated 3 times.

d Bona fide ribozyme target.

The target locations of the 56 sequenced clones are illustrated in FIG. 8. The histogram indicates that the target sites are fairly evenly distributed across the entire ICP4 gene, with the exception that no clones were identified targeting the 5'- and 3'-termini. It is unlikely that the library is devoid of members targeting these regions since the libraries are prepared with complexities far exceeding the total number of sites on the gene. It is even possible that target sites in these regions are similarly represented as those identified by the sequenced clones. Due to the small number of clones sequenced, it is likely that some larger gaps in the data could be observed even for a uniformly represented library, such as the gap between positions 966 and 1282.

Of the 56 sequences determined, 42 (75%) occurred only once, while four occurred multiple times (FIG. 8). Three were only mildly over-represented, with two or three occurrences compared with the single occurrence for the majority of clones. The three positions were 2054 and 3246, with two occurrences each, and position 2729, with three occurrences. One position, 3275, was significantly over-represented, occurring seven times. Five of the occurrences were observed within the 32 clones sequenced from the final library, and the other two were found at early stages of the construction. The over-representation of particular sites is likely caused by some local sequence and/or structure in the DNA that either stalls exonuclease III or causes it to fall off the template. P. Abarzua & K.J. Mariani, 81 Proc. Nat'l Acad. Sci. USA 2030-2034 (1984). Performing the exonuclease III deletion at higher temperatures might reduce this phenomenon if an inhibitory structure is forming at certain sequences. Higher temperature also allows for more distributive activity from the enzyme, J.D. Hoheisel, 209 Anal. Biochem. 238-246 (1993), which is desirable in this type of exonuclease III digestion. While it is possible that the exonuclease III digestion conditions may need to be optimized for each target cDNA, creating libraries larger than would be necessary to represent every position would ensure complete representation of all target sites.

Examination of the 31 clones obtained from the final library allowed determination of the overall effectiveness of the procedure. All 31 possessed a catalytic core, demonstrating the effectiveness of the use of CAT selection for this purpose. Nineteen of the 31 clones (61%) contained sequences that could potentially be ribozymes if the sequence that they targeted included the required NUH sequence at the correct location. These are shown in Table 1. Counted among these potential ribozymes were three clones that possess non-detrimental defects. One has a single nucleotide deleted from loop II of the ribozyme (Rz13). This produces a three-, instead of a four-nucleotide loop II. The site of this defect is the NruI site used to remove CAT from the catalytic core. The ends must have been damaged during this step for this clone. The other two non-detrimental defects were the result of incomplete digestion by BsmFI. These clones have a longer flanking arm corresponding to helix III (Rz12 and Rz14). This appears to be the result of a lack of cleavage of the BsmFI site on pASlib and, instead, an internal BsmFI site on ICP4 was used. These clones would be expected to produce functional ribozymes had they targeted an NUH sequence.

The remaining 12 clones (39% of 31) possessed defects that would prevent them from being potentially functional ribozymes. Four of these (13%) were defective in that they were cleaved twice with HphI. As discussed above, it is likely that this defect can be reduced to close

to zero by performing the HphI digestion under "sub-single hit" conditions. Three (9.7%) were missing 1 nucleotide from one end of the catalytic core. Since the deletion always occurred at the same end of the cassette and the thermostable polymerase used to make the cassette does not contain any 5' to 3' exonuclease activity, the PCR primer constituting that end of the cassette must have been contaminated with a small percentage of a failure fragment of the DNA synthesis. This defect can be eliminated by better purification of the primers. Five clones (16%) possessed the catalytic core in the incorrect orientation. This is in contrast to the expected 50% if there were no selection for orientation. Incorrectly oriented clones could be eliminated by moving the promoter for the CAT gene outside the MCS of pASlib. Finally, three clones were the result of various unknown cloning artifacts.

Therefore, the success rate of this library was 61%. As discussed, a few procedural changes would increase the success rate to 70-80%. This could be increased a further 16% by placing the CAT promoter outside the MCS. Even at 61%, the success rate is more than adequate. This just means that it is necessary to screen an antisense library 140% the size needed if 100% success were achieved. This would still be a small library relative to a non-directed library approach.

Three of the 31 clones (9.7%) targeted a site on the ICP4 mRNA that contained a uridine at the proper position of the consensus NUH site (Rz3, Rz5, and Rz16). Of the three, only one targeted a consensus NUH site (Rz16). Due to the unusually high G/C content of the ICP4 genomic fragment used to make the ribozyme library, only 9.2% of the nucleotides in the mRNA are uridines, of which 203 occur as an NUH triplet. The fact that the percentage of sequenced clones in the library targeting an NU site is virtually identical to the percentage of uridines in the ICP4 gene suggests that the library is unbiased and likely to contain a fairly uniform distribution of target sites.

The use of a direct library for target site selection significantly simplifies the screening process, since only very small libraries need be prepared and assayed. For ICP4, assuming the library contains a uniform distribution of the 4475 distinct sequences (4489-14), a library of 67,125 (15-fold excess) is expected to have a probability of 99.9% of containing all sequences. W. Feller, An Introduction to Probability Theory and Its Applications (3d ed. 1968). Based on a  $\chi^2$  goodness-of-fit analysis of the 56 sequences, the multiples observed at positions 2729 and 3275 occur with a higher frequency than would be expected for a uniform distribution. All other positions are consistent with a uniform distribution. Correcting for the two over-represented sequences, a library of 81,057 (18-fold excess) is expected to contain all sequences with

probability of 99.9%. Preparation, manipulation, and screening of such a library is well within the limitations of current practice. In contrast, a non-directed library targeting 14 nucleotides would require a minimum size of  $2.7 \times 10^8$  ( $4^{14}$ ). The ability to prepare and screen such a library is questionable. Even if possible, the vast majority of members of the library are directed at non-target genes. Inhibition of non-target genes could pose problems in interpreting the results.

5



## CLAIMS

We claim:

1. A method for generating an antisense library targeted to a selected RNA transcript comprising:

5 (a) preparing a double-stranded cDNA, comprising a first end, a second end, and a central site thereof, from the selected RNA transcript and cloning the cDNA in a cloning vector comprising a promoter configured such that an antisense transcript of the cDNA is synthesized upon transcription mediated by the promoter, resulting in a cloned cDNA;

10 (b) creating a plurality of deletion derivatives of said cloned cDNA wherein each of said plurality of deletion derivatives has a deletion extending from said first end into the cloned cDNA such that the plurality of deletion derivatives comprises a deletion library comprising deletions extend serially into the cDNA;

15 (c) reducing the size of the cDNA contained in the deletion library to a preselected size by removing a portion of the cDNA from the second end thereof to result in a fragment library;

(d) inserting an antisense gene DNA into the central site of the cDNA in the fragment library, thereby obtaining the antisense library.

2. The method of claim 1 wherein said cloning vector comprises a multi-cloning sequence represented by SEQ ID NO:1.

20 3. The method of claim 1 wherein said cloning vector comprises a multi-cloning sequence comprising SEQ ID NO:2 and SEQ ID NO:3.

4. The method of claim 1 wherein said plurality of deletion derivatives is created with exonuclease III resection of the cloned cDNA.

25 5. The method of claim 1 wherein said reducing the size of the cDNA contained in the deletion library to a preselected size comprises digesting the deletion library with a type IIS restriction endonuclease.

30 6. The method of claim 1 wherein said inserting an antisense gene DNA into the central site of the cDNA in the fragment library comprises digesting the fragment library with a type IIS restriction endonuclease, thereby creating said central site, and ligating the antisense gene DNA at the central site.

7. The method of claim 1 wherein said antisense gene DNA comprises a ribozyme catalytic core.

8. The method of claim 1 wherein said ribozyme catalytic core is a hammerhead

ribozyme catalytic core.

9. A method for generating a library of DNA fragments of a selected size wherein said fragments collectively span all possible sites of the selected size in a source DNA comprising a first end, a second end, and a central site thereof, comprising:

- 5 (a) cloning the source DNA in a cloning vector;
- (b) creating a plurality of deletion derivatives of said cloned source DNA wherein each of said plurality of deletion derivatives has a deletion extending from said first end into the cloned DNA such that the plurality of deletion derivatives comprises a deletion library comprising deletions extend serially into the cloned DNA;
- 10 (c) reducing the size of the DNA contained in the deletion library to a preselected size by removing a portion of the DNA from the second end thereof to result in the library of fragments.

10. The method of claim 9 wherein said cloning vector comprises a multi-cloning sequence represented by SEQ ID NO:1.

15 11. The method of claim 9 wherein said cloning vector comprises a multi-cloning sequence comprising SEQ ID NO:2 and SEQ ID NO:3.

12. The method of claim 9 wherein said plurality of deletion derivatives is created with exonuclease III resection of the cloned DNA.

20 13. The method of claim 9 wherein said reducing the size of the DNA contained in the deletion library to a preselected size comprises digesting the deletion library with a type IIS restriction endonuclease.

14. The method of claim 9 wherein said source DNA is a double-stranded cDNA prepared from an RNA transcript.

- 25 15. pASlib (SEQ ID NO:7).
16. pShuttle (SEQ ID NO:14).
17. pBK (SEQ ID NO:17).

18. A multi-cloning sequence represented by SEQ ID NO:1.

19. A multi-cloning sequence comprising SEQ ID NO:2 and SEQ ID NO:3.

30 20. A method for identifying target sites for antisense-mediated inhibition of a selected gene comprising:

- (a) constructing a directed antisense library targeted at said selected gene wherein said library is contained in a cloning vector having a promoter configured for transcribing antisense transcripts from said directed antisense library in suitable cells wherein the selected

gene is expressed as a target transcript;

(b) transforming a plurality of said suitable cells such that each of said plurality of suitable cells transcribes an antisense transcript that has access to the target transcript for potential inactivation thereof;

5 (c) identifying a cell wherein an antisense transcript inactivates the target transcript; and

(d) analyzing the antisense transcript that inactivates the target transcript and determining a target site on the antisense transcript that is associated with inactivation of the target transcript.

10 21. A method for identifying target sites for antisense-mediated inhibition of a selected gene comprising:

(a) constructing a directed antisense library targeted at said selected gene wherein said library is contained in a cloning vector having a promoter configured for transcribing antisense transcripts from said directed antisense library *in vitro*;

15 (b) transcribing antisense transcripts from said directed antisense library *in vitro*;

(c) incubating said antisense transcripts with a lysate from a cell containing target transcripts transcribed from said selected gene such that antisense transcripts targeted to the target transcripts bind to such target transcripts; and

(d) analyzing the antisense transcripts that bind the target transcript and determining  
20 a target site on the antisense transcript that is associated with binding of the target transcript.

1/8




Fig. 1A





Fig. 1B

**Fig. 2**

3/8




Fig. 3

4/8




Fig. 4

5/8




Fig. 5A




Fig. 5B



6/8




Fig. 6A








Fig. 6B



**Fig. 7B**




**Fig. 7C**



**Fig. 7A**

8/8

**Fig. 8**

## SEQUENCE LISTING

<110> Ruffner, Duane E.  
Pierce, Michael L.  
Chen, Zhidong

<120> Directed Antisense Libraries

<130> T6678.PCT

<140> PCT/US99/06742

<141> 1999-03-28

<150> 60/079,792

<151> 1998-03-28

<160> 34

<170> Word97

<210> 1

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Multiple cloning site for use in making deletion libraries.

<400> 1

gcttggatgc gcattcgata tcgtttaaac gcccgggcgc ggccgcggcg 50

cctccagtcg ac 62

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Portion of a multiple cloning site for use in making deletion libraries.

<400> 2

gtcgacggga ctgcaggttt aaac 24

<210> 3

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Portion of a multiple cloning site for use in making deletion libraries.

<400> 3

gaagacagtc accaagcttc agc 23

<210> 4

<211> 23

<212> DNA

<213> Unknown

<220>

<223> Catalytic core of hammerhead ribozyme.

<400> 4

ctgatgaggt cgcgagaccg aaa 23

<210> 5

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for construction of pASlib.

<400> 5

aagcttggtg actgtcttcg agctcgaatt catcgatatc tagagttta 49

<210> 6

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for construction of pASlib.

<400> 6

gtcgacggga ctgcagggtt aaactctaga tatc 34

<210> 7

<211> 2077

<212> DNA

<213> Artificial Sequence

<220>

<223> pASlib

<400> 7

tcagtgggaac gaaaactcac gttaagggat tttggtcatg aattgtcgac 50  
gggactgcag gtttaaactc tagatatcga tgaattcgag ctcgaagaca 100

gtcaccaagc ttattcccag agtcacgctc agaagaactc gtcaagaagg 150  
cgatagaagg cgatgcgctg cgaatcggga gcggcgatac cgtaaagcac 200  
gaggaagcgg tcagcccatt cgccgccaag ctcttcagca atatcacggg 250  
tagccaacgc tatgtcctga tagcgggtccg ccacaccag ccggccacag 300  
tcgatgaatc cagaaaagcg gccattttcc accatgatat tcggcaagca 350  
ggcatcgcca tgggtcacga cgagatcctc gccgtcgggc atgcgcgcct 400  
tgagcctggc gaacagttcg gctggcgcgga gcccctgatg ctcttcgtcc 450  
agatcatcct gatcgacaag accggcttcc atccgagtac gtgctcgctc 500  
gatgcgatgt ttcgcttggt ggtcgaatgg gcaggtagcc ggatcaagcg 550  
tatgcagccg ccgcattgca tcagccatga tggatacttt ctcggcagga 600  
gcaagatgag atgacaggag atcctgcccc ggcacttcgc ccaatagcag 650  
ccaatccctt cccgcttcag tgacaacgctc gagcacagct gcgcaaggaa 700  
cgcccgtcgt ggcaagccac gatagccgcg ctgcctcgctc ttgcagttca 750  
ttcagggcac cggacaggtc ggtcttgaca aaaagaaccg gccgcccctg 800  
cgctgacagc cggaacacgg cggcatacga ggagccgatt gtctgtttgtg 850  
cccagtcata gccgaatagc ctctccaccc aagcggccgg agaacctgcg 900  
tgcaatccat cttgtttcaat catgcgaaac gatcctcatc ctgtctcttg 950  
atcagatctt gatccccctgc gccatcagat ccttggcggc aagaaagcca 1000  
tccagtttac tttgcagggc ttcccaacct taccagaggt cgccccagct 1050  
ggcaattccg gttcgcttgc tgtccataaa accgcccagt ctagctatcg 1100  
ccatgtaagc ccaactgcaag ctacctgctt tctctttgcg cttgcgtttt 1150  
cccttgtcca gatagcccag tagtgacatt catccgggggt cagcaccggt 1200  
tctgcggact ggctttctac gtgttccgct tcctttagca gcccttgcg 1250  
cctgagtgct tgcggcagcg tgaagctgct tcctcgctca ctgactcgct 1300

gcgctcggtc gttegggtgc ggcgagcggc atcagctcac tcaaaggcgg 1350  
 taatacgggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 1400  
 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc 1450  
 gttttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct 1500  
 caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcggtt 1550  
 cccctggaa gctccctcgt gcgctctcct gttccgaccc tgccgcttac 1600  
 cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcaat 1650  
 gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg 1700  
 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg 1750  
 taactatcgt cttgagtcca acccggttaag acacgactta tcgccactgg 1800  
 cagcagccac tggtaacagg attagcagag cgaggtatgt aggcgggtgct 1850  
 acagagttct tgaagtgggt gcctaactac ggctacacta gaaggacagt 1900  
 atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 1950  
 gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 2000  
 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 2050  
 tttgatcttt tctacggggc ctgacgc 2077

<210> 8

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying a 3'-UTR/poly(A) segment.

<400> 8

ccgagggcaa aggaataggc gggactctgg ggt 33



<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying a 3'-UTR/poly(A) segment.

<400> 9

ctcgagggtcg acgggatcca g 21

<210> 10

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying a hygromycin coding region.

<400> 10

ggatgaggat cgtttcgcac gaaaaagcct gaa 33

<210> 11

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying a hygromycin coding region.

<400> 11

accccagagt cccgcctatt cctttgccct cgg 33

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying an amp/SV40 early promoter.

<400> 12

cgtcaggtgg cacttttcgg 20

<210> 13

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer for amplifying the amp/SV40 early promoter.

<400> 13

ttcaggcttt ttcatgcgaa acgatacctca tcc 33

<210> 14

<211> 8705

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; pShuttle

&lt;400&gt; 14

tcgagcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc 50  
 agacccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc 100  
 gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt 150  
 tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt 200  
 cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtaggttag 250  
 gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta 300  
 atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg 350  
 gttggactca agacgatagt taccggataa ggcgacgcgg tcgggctgaa 400  
 cgggggggttc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa 450  
 ctgagatacc tacagcgtga gcattgagaa agcgccacgc ttcccgaagg 500  
 gagaaaggcg gacaggtatc cggtaaagcg cagggtcgga acaggagagc 550  
 gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc 600  
 gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg 650  
 ggggcgagc ctatggaaaa acgccagcaa cgcggccttt ttacgggttcc 700  
 tggccttttg ctggcctttt gctcacatgt tctttcctgc gttatcccct 750  
 gattctgtgg ataaccgtat taccgccttt gagtgagctg ataccgctcg 800  
 ccgcagccga acgaccgagc gcagcgagtc agtgagcgag gaagccgtca 850  
 ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttatTTTT 900  
 ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa 950  
 tgcttcaata atattgaaaa aggaagagtc ctgaggcgga aagaaccagc 1000  
 tgtggaatgt gtgtcagtta ggggtgtgaa agtccccagg ctccccagca 1050  
 ggcagaagta tgcaaagcat gcattctcaat tagtcagcaa ccagggtgtg 1100

aaagtcccca ggctccccag caggcagaag tatgcaaagc atgcatctca 1150  
attagtcagc aaccatagtc ccgcccctaa ctccgcccac cccgccccta 1200  
actccgcccc gttccgcccc ttctccgccc catggctgac taattttttt 1250  
tatttatgca gaggccgagg ccgcctcggc ctctgagcta ttccagaagt 1300  
agtgaggagg ctttttttga ggcctaggct tttgcaaaga tcgatcaaga 1350  
gacaggatga ggatcgtttc gcatgaaaaa gcctgaactc accgcgacgt 1400  
ctgtcgagaa gtttctgatc gaaaagttcg acagcgtctc cgacctgatg 1450  
cagctctcgg agggcgaaga atctcgtgct ttcagcttcg atgtaggagg 1500  
gcgtggatat gtcctgcggg taaatagctg cgccgatggt ttctacaaag 1550  
atcgttatgt ttatcggcac tttgcatcgg ccgcgctccc gattccggaa 1600  
gtgcttgaca ttggggaatt cagcgagagc ctgacctatt gcatctcccg 1650  
ccgtgcacag ggtgtcacgt tgcaagacct gcctgaaacc gaactgcccc 1700  
ctgttctgca gccggtcgcg gaggccatgg atgcgatcgc tgcggccgat 1750  
cttagccaga cgagcggggt cggcccatc ggaccgcaag gaatcgggtca 1800  
atacactaca tggcgtgatt tcatatgcgc gattgctgat ccccatgtgt 1850  
atcactggca aactgtgatg gacgacaccg tcagtgcgtc cgtcgcgcag 1900  
gctctcgatg agctgatgct ttgggcccag gactgccccg aagtccggca 1950  
cctcgtgcac gcggatttcg gctccaacaa tgtcctgacg gacaatggcc 2000  
gcataacagc ggtcattgac tggagcgagg cgatgttcgg ggattcccaa 2050  
tacgaggtcg ccaacatctt cttctggagg ccgtggttgg cttgtatgga 2100  
gcagcagacg cgctacttcg agcggaggca tccggagctt gcaggatcgc 2150  
cgcggtccg ggcgtatatg ctccgcattg gtcttgacca actctatcag 2200  
agcttggttg acggcaattt cgatgatgca gcttggggcg agggtcgatg 2250  
cgacgcaatc gtccgatccg gagccgggac tgtcggggcg acacaaatcg 2300

ccgcgagaag cgcgggccgtc tggaccgatg gctgtgtaga agtactcgcc 2350  
gatagtggaa accgacgccc cagcactcgt ccgagggcaa aggaataggc 2400  
gggactctgg ggttcgaaat gaccgaccaa gcgacgcccc acctgccatc 2450  
acgagatttc gattccaccg ccgccttcta tgaaagggtg ggcttcggaa 2500  
tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg 2550  
ctggagttct tcgcccaccc caacttgttt attgcagctt ataatggtta 2600  
caaataaagc aatagcatca caaatctcac aaataaagca tttttttcac 2650  
tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc 2700  
tggatccgat gtacgggcca gatatacgcg ttgacattga ttattgacta 2750  
gttattaata gtaatcaatt acgggggtcat tagttcatag cccatatatg 2800  
gagttccgcg ttacataact tacggtaaata ggcccgccctg gctgaccgcc 2850  
caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa 2900  
cgccaatagg gactttccat tgacgtcaat ggggtggacta tttacggtaa 2950  
actgcccact tggcagtaca tcaagtgtat catatgccaa gtacgcccc 3000  
tattgacgtc aatgacggta aatggcccg ctaggcattat gcccagtaca 3050  
tgaccttatg ggactttcct acttggcagt acatctacgt attagtcatc 3100  
gctattacca tggatgatgcg gttttggcag tacatcaatg ggcgtggata 3150  
gcggtttgac tcacggggat ttccaagtct ccacccatt gacgtcaatg 3200  
ggagtttggt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac 3250  
aactccgccc cattgacgca aatgggcggt aggcgtgtac ggtgggaggt 3300  
ctatataagc agagctctct ggctaactag agaaccact gcttaactgg 3350  
cttatcgaaa ttaatacgac tcactatagg gagaccaag cttggtaccg 3400  
agctcggatc cactagtaac ggccgccagt gtgctggaat tctgcagata 3450  
tccatcacac tggcgggcgc tcgagcatgc atctagaggg ccctattcta 3500  
tagtgtcacc taaatgctag agctcgctga tcagcctcga ctgtgccttc 3550

tagttgccag ccattctgttg tttgcccctc ccccggtgcct tccttgaccc 3600  
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca 3650  
tcgcattgtc tgagtaggtg tcattctatt ctgggggggtg ggggtggggca 3700  
ggacagcaag ggggaggatt gggaagacaa tagcaggcat gctgggggatg 3750  
cgggtgggctc tatggcttct gaggcggaaa gaaccaggat ccccgccgc 3800  
cggacgaact aaacctgact acggcatctc tgccccttct tcgctggtac 3850  
gaggagcgct tttgttttgt attggtcacg gggcagtgca tgtaatccct 3900  
tcagttggtt ggtacaactt gccaaactggg ccctgttcca catgtgacac 3950  
gggggggggac caaacacaaa ggggttctct gactgtagtt gacatcctta 4000  
taaattggatg tgcacatttg ccaacactga gtggctttca tcctggagca 4050  
gactttgcag tctgtggact gcaacacaac attgccttta tgtgtaactc 4100  
ttggctgaag ctcttacacc aatgctgggg gacatgtacc tcccaggggc 4150  
ccaggaagac tacgggaggc tacaccaacg tcaatcagag gggcctgtgt 4200  
agctaccgat aagcggaccc tcaagagggc attagcaata gtgtttataa 4250  
ggcccccttg ttaaccctaa acgggtagca tatgcttccc gggtagtagt 4300  
atatactatc cagactaacc ctaattcaat agcatatgtt acccaacggg 4350  
aagcatatgc tatcgaatta gggtagtaa aagggtccta aggaacagcg 4400  
atatctccca ccccatgagc tgtcacggtt ttatttacat ggggtcagga 4450  
ttccacgagg gtagtgaacc attttagtca caagggcagt ggctgaagat 4500  
caaggagcgg gcagtgaact ctctgaatc ttcgcctgct tcttcattct 4550  
ccttcgttta gctaatagaa taactgctga gttgtgaaca gtaaggtgta 4600  
tgtgaggtgc tcgaaaacaa ggtttcaggt gacgccccca gaataaaatt 4650  
tggaacggggg gttcagtggt ggcattgtgc tatgacacca atataaccct 4700  
caciaacccc ttgggcaata aatactagt taggaatgaa acattctgaa 4750

tatctttaac aatagaaatc catgggggtgg ggacaagccg taaagactgg 4800  
atgtccatct cacacgaatt tatggctatg ggcaacacat aatcctagtg 4850  
caatatgata ctgggggttat taagatgtgt cccaggcagg gaccaagaca 4900  
gggtgaaccat gttgttacac tctattttga acaaggggaa agagagtggg 4950  
cgccgacagc agcggactcc actggttgct tctaacaccc ccgaaaatta 5000  
aacgggggctc cacgccaatg gggcccataa acaaagacaa gtggccactc 5050  
ttttttttga aattgtggag tgggggcacg cgtcagcccc cacacgccgc 5100  
cctgcgggtt tggactgtaa aataaggggtg taataacttg gctgattgta 5150  
accccgctaa ccactgcggt caaaccactt gccacaaaa ccactaatgg 5200  
caccgccggg aatacctgca taagtaggtg ggcgggcaa gataggggcg 5250  
cgattgctgc gatctggagg acaaattaca cacacttgcg cctgagcgcc 5300  
aagcacaggg ttgttggtcc tcatattcac gaggtcgctg agagcacggt 5350  
gggctaattg tgccatgggt agcatatact acccaaatat ctggatagca 5400  
tatgctatcc taatctatat ctgggtagca taggctatcc taatctatat 5450  
ctgggtagca tatgctatcc taatctatat ctgggtagta tatgctatcc 5500  
taatttatat ctgggtagca taggctatcc taatctatat ctgggtagca 5550  
tatgctatcc taatctatat ctgggtagta tatgctatcc taatctgtat 5600  
ccgggtagca tatgctatcc taatagagat taggtagta tatgctatcc 5650  
taatttatat ctgggtagca tatactaccc aaatatctgg atagcatatg 5700  
ctatcctaata ctatatctgg gtagcatatg ctatcctaata ctatatctgg 5750  
gtagcatagg ctatcctaata ctatatctgg gtagcatatg ctatcctaata 5800  
ctatatctgg gtagtatatg ctatcctaata ttatatctgg gtagcatagg 5850  
ctatcctaata ctatatctgg gtagcatatg ctatcctaata ctatatctgg 5900  
gtagtatatg ctatcctaata ctgtatccgg gtagcatatg ctatcctcat 5950  
gcatatacag tcagcatatg ataccagta gtagagtggg agtgctatcc 6000

tttgcataatg ccgccacctc ccaagggggc gtgaattttc gctgcttgtc 6050  
cttttcctgc tggttgctcc cattcttagg tgaatttaag gaggccaggc 6100  
taaagccgctc gcatgtctga ttgctcacca ggtaaagtgc gctaattgtt 6150  
tccaacgcga gaaggtgttg agcgcgaggc tgagtgcagt gacaacatgg 6200  
gtatgcccaa ttgccccatg ttgggaggac gaaaatgggtg acaagacaga 6250  
tggccagaaa tacaccaaca gcacgcata tgtctactgg ggatttattc 6300  
tttagtgcgg gggaatacac ggcttttaac acgattgagg gcgtctccta 6350  
acaagttaca tcaactcctgc ccttcctcac cctcatctcc atcacctcct 6400  
tcatctccgt catctccgtc atcacctcc gcggcagccc cttccaccat 6450  
aggtggaaac caggaggga aatctactcc atcgtcaaag ctgcacacag 6500  
tcaccctgat attgcaggta ggagcgggct ttgtcataac aaggtcctta 6550  
atcgcatact tcaaaacctc agcaaataa tgagtgtgta aaaagaccat 6600  
gaaataacag acaatggact cccttagcgg gccagggtgt gggccgggtc 6650  
caggggcat tcaaagggg agacgactca atgggtgtaag acgacattgt 6700  
ggaatagcaa gggcagttcc tcgccttagg ttgtaaagg aggtcttact 6750  
acctccatat acgaacacac cggcgaccca agttccttcg tcggtagtcc 6800  
tttctacgtg actcctagcc aggaggggcc ttaaaccctt tgcaatgttc 6850  
tcaaatttcg ggttggaacc tccttgacca cgatgctttc caaaccaccc 6900  
tccttttttg cgctgcctc catcacctg accccggggc ccagtgcctg 6950  
ggccttctcc tgggtcatct gcggggccct gctctatcgc tcccgggggc 7000  
acgtcagggt caccatctgg gccaccttct tgggtggtatt caaaataatc 7050  
ggcttcccct acagggtgga aaaatggcct tctacctgga gggggcctgc 7100  
gcggtggaga ccgggatgat gatgactgac tactgggact cctgggcctc 7150  
ttttctccac gtccacgacc tctccccctg gctctttcac gacttcccc 7200



cctgggtcttt tcacgtcctc taccocggcg gcctccacta cctcctcgac 7250  
cccggcctcc actacctcct cgaccccggc ctccactgcc tcctcgaccc 7300  
cggcctccac ctctgtctcc tgcccctcct gctcctgccc ctctcctgc 7350  
tcctgcccct cctgcccctc ctgtctcctgc ccctcctgcc cctcctgctc 7400  
ctgcccctcc tgcccctcct gctcctgccc ctctgcccc tcctcctgct 7450  
cctgcccctc ctgcccctcc tcctgtctcct gcccctcctg ccctcctgc 7500  
tcctgcccct cctgcccctc ctgtctcctgc ccctcctgcc cctcctgctc 7550  
ctgcccctcc tgctcctgcc cctcctgctc ctgcccctcc tgctcctgcc 7600  
cctcctgccc ctctgcccc tcctcctgct cctgcccctc ctgtcctgc 7650  
ccctcctgcc cctcctgccc ctctgtctcc tgcccctcct cctgtctctg 7700  
ccctcctgc ccctcctgcc cctcctcctg ctctgcccc tcctgcccct 7750  
cctcctgctc ctgcccctcc tcctgtctcct gcccctcctg ccctcctgc 7800  
ccctcctcct gctcctgccc ctctgcccc tcctcctgct cctgcccctc 7850  
ctctgtctcc tgcccctcct gcccctcctg ccctcctcc tgctcctgcc 7900  
cctcctcctg ctctgcccc tcctgcccct cctgcccctc ctgcccctcc 7950  
tcctgtctcct gcccctcctc ctgtctcctgc ccctcctgct cctgcccctc 8000  
ccgtcctgc tcctgtctcct gttccaccgt gggtccttt gcagccaatg 8050  
caacttgagac gtttttgggg tctccggaca ccatctctat gtcttgggcc 8100  
tgatcctgag ccgcccgggg ctctggtct tccgcctcct cgtcctcgtc 8150  
ctcttccccg tcctcgtcca tggttatcac ccctctttct ttgaggtcca 8200  
ctgcccggg agccttctgg tccagatgtg tctcccttct ctctaggcc 8250  
atttccaggt cctgtacctg gcccctcgtc agacatgatt cacactaaaa 8300  
gagatcaata gacatcttta ttagacgacg ctcaagtgaat acagggagtg 8350  
cagactcctg cccctccaa cagccccccc accctcatcc ccttcatggt 8400  
cgctgtcaga cagatccagg tctgaaaatt ccccatcctc cgaaccatcc 8450

tcgtcctcat caccaattac tcgcagcccg gaaaactccc gctgaacatc 8500  
 ctcaagatth ggcgcctgag cctcaagcca ggcctcaaht tcctcgtccc 8550  
 ccttttttgct ggacggtagg gatgggggatt ctccgggaccc ctctctctcc 8600  
 tcttcaaggt caccagacag agatgctact ggggcaacgg aagaaaagct 8650  
 ggggtgcggcc tgtgaggatc agcttatcga tgataagctg tcaaacaatga 8700  
 gaatt 8705

<210> 15  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> CatCass1

<400> 15

ctgatgaggt cgcgactagt gttgacaat 29

<210> 16  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> CatCass2

<400> 16

tccggtctcg cgagcagggt agtgaca 27

<210> 17

<211> 5658

<212> DNA

<213> Artificial Sequence

<220>

<223> pBK

<400> 17

ctagttctgg cgcagaacca tggcctttgt ccagtttaac tggggacaag 50  
gccaaagattc ctaggctcgc aaaacatgtc tgtcatgcac tttccttcct 100  
gagggtcatgg tttggctgca ttccatgggt aagcagctcc tccctgtgag 150  
tcatgcactt tccttcctga ggtcatgggt tggctgcatt cccctgtgag 200  
tcatgcactt tccttcctga ggtcatgggt tggctgcatt ccatgggtaa 250  
gcagctcctc cctgtggcct ttttttttat aatatataag aggccgaggc 300  
cgctctgcc tccacccttt ctctcaagta gtaagggtgt ggaggctttt 350  
tctgaggcct agcaaaacta tttggggaaa tccctattct tttgcaattt 400  
ttgcaaaaat ggataaagtt cttaacaggg aagaatccat ggagctcatg 450  
gaccttttag gccttgaaag agctgcctgg ggaaatcttc ccttaatgag 500  
aaaagcttat ttaaggaagt gtaaggaatt tcatcctgac aaagggggcg 550  
acgaggataa aatgaagaga atgaatactt tgtataaaaa aatggagcag 600  
gatgtaaagg tagctcatca gcctgatttt ggaacttgga gtagctcaga 650  
ggtttgtgct gattttcctc tttgcccaga taccctgtac tgcaaggaat 700  
ggcctatttg ttccaaaaag ctttctgtgc actgcccttg catgctatgt 750  
cagcttagat taaggcattt aaatagaaaa tttttaagaa aagagccctt 800  
ggtttgata gattgctact gcattgactg cttcacacag tggtttggt 850  
tagacctaac tgaagaaact ctgcaatggt gggtcctaat aattggagaa 900

actcccttca gagatctaaa gctttaaggt aactaactta tatttagata 950  
aataataaaa tattaaaagg ccctaagtaa ttatTTTTTT tatagggtgcc 1000  
aacctatgga acagaagagt gggagtcctg gtggagttcc tttaatgaaa 1050  
aatgggatga agatttattt tgccatgaag atatgtttgc cagtgatgaa 1100  
gaagcaacag cagattctca aactcaaca ccacccaaaa aaaaaagaaa 1150  
ggtagaagac cctaaagact ttccctctga tctacaccag tttcttagtc 1200  
aagctgtatt tagtaataga acccttgcct gctttgctgt gtatactact 1250  
aaagaaaaag ctcaaattct gtataaaaaa cttatggaaa aatattctgt 1300  
aacttttatt agtagacaca tgtgtgctgg gcataatatt atattctttt 1350  
taactccaca tagacataga gtttctgcaa ttaataattt ctgtcaaaag 1400  
ctgtgtacct ttagtTTTTT aatttgtaag ggtgttaata aggaatactt 1450  
actatatagt gccttaacta gagatccata ccatactata gaagaaagca 1500  
ttcaaggggg cttaaaggag catgatttta gcccagaaga gcctgaagaa 1550  
acaaagcagg tgtcttgga aattaattact gagtatgcag tagagacaaa 1600  
gtgtgaggat gtgtttttat tattaggtat gtatttagaa tttcaatata 1650  
atgtagagga gtgtaaaaag tgtcagaaaa aagaccagcc ttatcacttt 1700  
aagtatcatg aaaagcactt tgcaaagtct attatTTTTg cagaaagtaa 1750  
aatcaaaaa agtatttgtc agcaagcagt agatacagtt ttagctaaaa 1800  
aaagagtaga tacccttcat atgaccaggg aagaaagtct aacagaaaga 1850  
ttcaatcata tattagataa aatggattta atatttgag ctcatggaaa 1900  
tgctgtacta gaacaatata tggcagggtg tgcttggtg cactgtttgc 1950  
tacctaaaat ggattctgta atatttgatt ttttgactg tattgttttc 2000  
aatgtacctā aaagaagata ctggttattt aaaggtcca ttgatagtgg 2050  
aaaaacaaca ctagctgccg ggttattaga tttgtgtggt ggtaaagcct 2100  
taaagtataa cctacccatg gaaaggctaa ctttgagct aggtgtagct 2150

atagatcagt acatgggtgt ttttgaagat gtaaaaggga caggagctga 2200  
atcaaaggat ttgccttcag gacatggaat aaacaattta gacagtttga 2250  
gagattatth agatggaagt gttaaggtaa atttagaaaa gaaacattta 2300  
aacaaaagaa cccaaatatt tccaccaggc ttggttacia tgaatgagta 2350  
tcctgtccct aaaaccctgc aagctagatt tgtaagacia atagatttta 2400  
ggcccaaaat atatttaaga aaatccttac aaaactcaga gttcttactt 2450  
gaaaaaagaa ttttaciaag tggaatgacc ttgttgctac tgctaatttg 2500  
gtttaggcct gtagctgatt ttgcaactga tatacaatct agaattgttg 2550  
aatggaagga aaggctggat tctgagataa gtatgtatac tttttcaagg 2600  
atgaaatata atatatgctt ggggaaatgt attcttgata ttacaagaga 2650  
agaggattca gaaactgaag actctggaca tggatcaagc actgaatccc 2700  
aatcacaatg ctcttcccaa gtctcagata cttcagcccc tgctgaagat 2750  
tcccaaaggc cagaccccca tagtcaagag ttgcatttgt gtaaaggctt 2800  
tcagtgtttt aaaaggccta aaacaccacc cccaaaataa cacaagctta 2850  
aaagtggctt atacaaaagc agcatttatt aaatgtatat gtacaataaa 2900  
agcacctgtt taaagcattt tggtttgcaa ttgtccctgt ttgtcaatat 2950  
atcttatcat atctgggtcc cctggaagta actagatgat ccgctgtgga 3000  
atgtgtgtca gttagggtgt ggaaagtccc caggctcccc agcaggcaga 3050  
agtatgcaaa gcatctcaat tagtcagcaa ccagggtgtg aaagtcccca 3100  
ggctccccag caggcagaag tatgcaaagt aatagtaatc aattacgggg 3150  
tcattagtth atagcccata tatggagth cgcgttacat aacttacggg 3200  
aatggcccg cctggctgac cgcccaacga ccccgccca ttgacgtcaa 3250  
taatgacgta tgttcccata gtaacgcaa tagggactth ccattgacgt 3300  
caatgggtgg agtatthacg gtaaactgcc cacttggcag tacatcaagt 3350

gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaattggc 3400  
ccgcctggca ttatgcccag tacatgacct tatgggactt tcctacttgg 3450  
cagtacatct acgtattagt catcgctatt accatggcga tgcggttttg 3500  
gcagtacatc aatgggogtg gatagcgggt tgactcacgg ggatttccaa 3550  
gtctccaccc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa 3600  
cgggactttc caaaatgtcg taacaactcc gcccattga cgcaaattggg 3650  
cggtaggcgt gtacgggtggg aggtctatat aagcagagct ggtttagtga 3700  
accgtcagat ccgctagcgc taccggactc agatctcgag ctcaagctaa 3750  
tcatcggcgt agtatatcgg catagtataa tacgactcac tataggaggg 3800  
ccaccatggc caagttgacc agtgccgttc cggtgcttac cgcgcgcgac 3850  
gtcgccggag cggtcgagtt ctggaccgac cggctcgggt tctcccggga 3900  
cttcgtggag gacgacttcg ccggtgtggt ccgggacgac gtgaccctgt 3950  
tcatcagcgc ggtccaggac caggtggtgc cggacaacac cctggcctgg 4000  
gtgtgggtgc gcggcctgga cgagctgtac gccgagtggg cggaggtcgt 4050  
gtccacgaac ttccgggacg cctccggggc ggccatgacc gagatcggcg 4100  
agcagccgtg ggggcgggag ttcgccctgc gcgaccggc cggcaactgc 4150  
gtgcacttcg tggccgagga gcaggactga ccgacgccga ccaacaccgc 4200  
cgggggggag ctaactgaaa cacggaagga gacaataccg gaaggaaccc 4250  
gcgctatgac ggcaataaaa agacagaata aaacgcacgg tggtgggtcg 4300  
tttggtcata aacgcggggg tcggtcccag ggctggcact ctgtcgatac 4350  
cccaccgacg gcggcccacg ggtcgaattg cgcttccctg atgagaccga 4400  
aaggtcgaaa gtcgaaagac tcggaagcga aagcttgggt atgcattcga 4450  
tatcgtttaa acgcccgggc gcggccgcgg cgcctccagt cgacgaaagt 4500  
cggctctgcc aaaggcactg atgagtccga aaggacgaaa ccgacttgct 4550  
agataactga tcataatcag ccataaccaca tttgtagagg ttttacttgc 4600

tttaaaaaac ctccacacacc tccccctgaa cctgaaacat aaaatgaatg 4650  
caattgttgt tgtaacttg tttattgcag cttataatgg ttacaaataa 4700  
agcaatagca tcacaaatth cacaataaaa gcattttttt cactgcattc 4750  
tagttgtggt ttgtccaaac tcatcaatgt atcttaacgc gtaaattgta 4800  
agcgtaatac atgcggccca tgaccaaact cccttaacgt gagttttcgt 4850  
tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat 4900  
cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct 4950  
accagcgggtg gtttgtttgc cggatcaaga gctaccaact ctttttccga 5000  
aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagt 5050  
tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata 5100  
cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 5150  
cgtgtcttac cgggttggac tcaagacgat agttaccgga taaggcgcag 5200  
cggtcgggct gaacggggggg ttctgtcaca cagcccagct tggagcgaac 5250  
gacctacacc gaactgagat acctacagcg tgagcattga gaaagcgcca 5300  
cgcttcccga agggagaaaag gcggacaggt atccggtaag cggcagggtc 5350  
ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct 5400  
ttatagtctt gtcgggtttc gccacctctg acttgagcgt cgatttttgt 5450  
gatgctcgtc agggggggcg agcctatgga aaaacgccag caacgcggcc 5500  
tttttacggt tcctggcctt ttgctggcct tttgctcaca tgttctttcc 5550  
tgcgttatcc cctgattctg tggataaccg tattaccgcc tttgagtgag 5600  
ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc 5650  
gaggaagc 5658

<210> 18

<211> 178

<212> DNA

<213> Artificial Sequence

<220>

<223> Multi-cloning sequence flanked by two cis-acting ribozymes (CAR'a).

<400> 18

gagctcgctt ccctgatgag tccgaaagga cgaaagtoga aagactcgga 50  
agcgaaagct tggatgatgca ttcgatatcg tttaaaccgcc cgggcgcggc 100  
cgcggcgcct ccagtcgacg aaagtcgggtc tgccgaaagg cactgatgag 150  
tccgaaagga cgaaaccgac ttggtacc 178

<210> 19

<211> 14

<212> DNA

<213> herpes simplex virus

<400> 19

cgacgccgcc cgcc 14

<210> 20

<211> 13

<212> DNA

<213> herpes simplex virus

<400> 20

cugcgcgcgu ggc 13

<210> 21



<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 21

gcgccugcgc gggg 14

<210> 22  
<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 22

cgccgccgac gcgc 14

<210> 23  
<211> 13  
<212> DNA  
<213> herpes simplex virus  
<400> 23

ccccccucccc gcg 13

<210> 24  
<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 24

guggccgugu cgcg 14

<210> 25  
<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 25

gccacacggc ggcg 14

<210> 26  
<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 26

cgccgcgcgg ugcg 14

<210> 27  
<211> 14  
<212> DNA  
<213> herpes simplex virus  
<400> 27

cgccgcgcgg ugcg 14

<210> 28  
<211> 15  
<212> DNA  
<213> herpes simplex virus  
<400> 28

ccccugcgc gccuc 15

<210> 29

<211> 15

<212> DNA

<213> herpes simplex virus

<400> 29

gguggugcug uacuc 15

<210> 30

<211> 14

<212> DNA

<213> herpes simplex virus

<400> 30

gggcccgcgg uguc 14

<210> 31

<211> 14

<212> DNA

<213> herpes simplex virus

<400> 31

ccuggcgugc gagc 14

<210> 32

<211> 21

<212> DNA

<213> herpes simplex virus

<400> 32

ggggaccacc gacgccaugg c 21

<210> 33

<211> 14

<212> DNA

<213> herpes simplex virus

<400> 33

cguggcgcug gggc 14

<210> 34

<211> 14

<212> DNA

<213> herpes simplex virus

<400> 34

cgggauucgc uggg 14

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/06742**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12Q 1/68; C12N 15/00, 15/85; C07H 21/04

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.1, 91.31, 320.1, 375; 536/23.1, 23.2, 24.3, 24.33, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog: CAS, Medline, Biosis, Derwent Biotechnology Abstracts

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,496,698 A (DRAPER et al.) 5 March 1996, see entire patent.	1-21
A	US 5,525,468 A (MCSWIGGEN) 11 June 1996, see entire patent.	1-21
A	MATVEEVA et al. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Research. 1997, Vol. 25, No. 24, pages 5010-5016, see entire document.	1-21

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 JULY 1999

Date of mailing of the international search report

19 JUL 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN LE GUYADER

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/06742

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	PIERCE et al. Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Research. 1998, Vol. 26, No. 22, pages 5093-5101, see entire document.	1-21

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/06742

**A. CLASSIFICATION OF SUBJECT MATTER:**

**US CL :**

435/6, 91.1, 91.31, 320.1, 375; 536/23.1, 23.2, 24.3, 24.33, 24.5

**THIS PAGE BLANK (USPTO)**